Skip to Main Content
Table 1

Clinicopathological and prognostic characteristics of breast cancers (n = 247) dichotomized by cytokeratin 5/6 (CK5/6) status

VariableCK5/6−CK5/6+ORa [95% CI]P10-yr survivalNo. of eventsP valueb (survival)
Age of diagnosis (yr)        
 (25–50) 51 49 1.00  64.9% 31 … 
 [50–65] 101 46 0.47 [0.28–0.80] 0.005 75.3% 30 .048 
Tumor size (cm)        
 (0–2) 88 40 1.00  83.8% 17 … 
 [2–11] 56 53 2.08 [1.23–3.54] 0.008 58.6% 40 <.0001 
Nuclear grade        
 Grade 1 53 11 1.00  89.6% … 
 Grade 2 70 26 1.79 [0.81–3.94] 0.18 72.4% 22 .007 
 Grade 3 29 58 9.64 [4.38–21.2] 0.0001 54.9% 34 <.0001 
Lymph node status        
 Negative 75 49 1.00  82.0% 19 … 
 Positive 60 42 1.07 [0.63–1.83] 0.89 57.5% 38 .0002 
ER IHC        
 Negative 41 50 1.00  55.4% 35 … 
 Positive 111 45 0.33 [0.19–0.57] <0.0001 79.9% 26 <.0001 
p53 IHC        
 Negative 124 63 1.00  76.6% 36 … 
 Positive 27 32 2.33 [1.29–4.23] 0.006 54.2% 25 .0002 
HER2 IHC        
 Faint staining 139 80 1.00  74.3% 48 … 
 Weak/strong 13 15 2.01 [0.91–4.43] 0.099 45.8% 13 .004 
BRCA1 germ-line mutation        
 Negative 145 75 1.00  72.3% 52 … 
 Positive 20 5.52 [2.24–13.7] 0.0001 61.6% .20 
p27Kip1 IHC        
 Negative 79 62 1.00  65.0% 42 … 
 Positive 62 27 0.56 [0.32–0.97] 0.051 80.4% 14 .005 
Cyclin E IHC        
 Negative 128 51 1.00  77.0% 35 … 
 Positive 22 41 4.68 [2.54–8.62] 0.0001 51.4% 26 <.0001 
GMP IHC        
 None 128 64 1.00  74.5% 41 … 
 Few 12 22 3.67 [1.71–7.88] 0.0001 56.4% 14 .008 
 Moderate/many 12.0 [1.41–101.8] 0.008 21.4% <.0001 
Chemotherapy        
 No 85 42 1.00  79.7% 22 … 
 Yes 64 51 1.61 [0.96–2.72] 0.09 61.2% 38 .0023 
Hormonal therapy        
 No 68 53 1.00  61.2% 42 … 
 Yes 76 34 0.57 [0.33–0.99] 0.057 83.5% 16 .0008 
VariableCK5/6−CK5/6+ORa [95% CI]P10-yr survivalNo. of eventsP valueb (survival)
Age of diagnosis (yr)        
 (25–50) 51 49 1.00  64.9% 31 … 
 [50–65] 101 46 0.47 [0.28–0.80] 0.005 75.3% 30 .048 
Tumor size (cm)        
 (0–2) 88 40 1.00  83.8% 17 … 
 [2–11] 56 53 2.08 [1.23–3.54] 0.008 58.6% 40 <.0001 
Nuclear grade        
 Grade 1 53 11 1.00  89.6% … 
 Grade 2 70 26 1.79 [0.81–3.94] 0.18 72.4% 22 .007 
 Grade 3 29 58 9.64 [4.38–21.2] 0.0001 54.9% 34 <.0001 
Lymph node status        
 Negative 75 49 1.00  82.0% 19 … 
 Positive 60 42 1.07 [0.63–1.83] 0.89 57.5% 38 .0002 
ER IHC        
 Negative 41 50 1.00  55.4% 35 … 
 Positive 111 45 0.33 [0.19–0.57] <0.0001 79.9% 26 <.0001 
p53 IHC        
 Negative 124 63 1.00  76.6% 36 … 
 Positive 27 32 2.33 [1.29–4.23] 0.006 54.2% 25 .0002 
HER2 IHC        
 Faint staining 139 80 1.00  74.3% 48 … 
 Weak/strong 13 15 2.01 [0.91–4.43] 0.099 45.8% 13 .004 
BRCA1 germ-line mutation        
 Negative 145 75 1.00  72.3% 52 … 
 Positive 20 5.52 [2.24–13.7] 0.0001 61.6% .20 
p27Kip1 IHC        
 Negative 79 62 1.00  65.0% 42 … 
 Positive 62 27 0.56 [0.32–0.97] 0.051 80.4% 14 .005 
Cyclin E IHC        
 Negative 128 51 1.00  77.0% 35 … 
 Positive 22 41 4.68 [2.54–8.62] 0.0001 51.4% 26 <.0001 
GMP IHC        
 None 128 64 1.00  74.5% 41 … 
 Few 12 22 3.67 [1.71–7.88] 0.0001 56.4% 14 .008 
 Moderate/many 12.0 [1.41–101.8] 0.008 21.4% <.0001 
Chemotherapy        
 No 85 42 1.00  79.7% 22 … 
 Yes 64 51 1.61 [0.96–2.72] 0.09 61.2% 38 .0023 
Hormonal therapy        
 No 68 53 1.00  61.2% 42 … 
 Yes 76 34 0.57 [0.33–0.99] 0.057 83.5% 16 .0008 
a

OR, odds ratio; CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; GMP, glomeruloid microvascular proliferation.

Close Modal

or Create an Account

Close Modal
Close Modal